Latest Insider Transactions at Annexon, Inc. (ANNX)
This section provides a real-time view of insider transactions for Annexon, Inc. (ANNX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Annexon, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Annexon, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 01
2021
|
Douglas Love PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+50.0%
|
$500
$1.41 P/Share
|
|
Mar 31
2021
|
Douglas Love PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
7,102
-100.0%
|
$198,856
$28.11 P/Share
|
|
Mar 31
2021
|
Douglas Love PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,102
+50.0%
|
$7,102
$1.41 P/Share
|
|
Mar 30
2021
|
Douglas Love PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
3,750
-75.33%
|
$90,000
$24.53 P/Share
|
|
Mar 30
2021
|
Douglas Love PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+50.0%
|
$3,750
$1.41 P/Share
|
|
Mar 29
2021
|
Douglas Love PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
3,750
-80.89%
|
$97,500
$26.23 P/Share
|
|
Mar 29
2021
|
Douglas Love PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+50.0%
|
$3,750
$1.41 P/Share
|
|
Mar 25
2021
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
SELL
Open market or private sale
|
Direct |
16,175
-86.47%
|
$469,075
$29.24 P/Share
|
|
Mar 25
2021
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
16,175
+28.39%
|
$48,525
$3.26 P/Share
|
|
Mar 24
2021
|
Sanjay Keswani EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,995
-100.0%
|
$119,850
$30.17 P/Share
|
|
Mar 24
2021
|
Sanjay Keswani EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,995
+50.0%
|
$27,965
$7.49 P/Share
|
|
Mar 23
2021
|
Jennifer Lew EVP & CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-33.17%
|
$140,000
$28.37 P/Share
|
|
Mar 23
2021
|
Jennifer Lew EVP & CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+41.67%
|
$35,000
$7.49 P/Share
|
|
Jul 28
2020
|
Clarus Lifesciences Iii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
200,000
+6.82%
|
$3,400,000
$17.0 P/Share
|
|
Jul 28
2020
|
Clarus Lifesciences Iii, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,530,635
+29.84%
|
-
|
|
Jul 28
2020
|
Redmile Group, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,596,222
+50.0%
|
-
|
|
Jul 28
2020
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
400,000
+10.98%
|
$6,800,000
$17.0 P/Share
|
|
Jul 28
2020
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,841,628
+30.05%
|
-
|
|
Jul 28
2020
|
James E Flynn > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
700,000
+30.2%
|
$11,900,000
$17.0 P/Share
|
|
Jul 28
2020
|
James E Flynn > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
917,828
+50.0%
|
-
|